Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel
Melanie D. Swift, Laura E. Breeher, Aaron J. Tande, Christopher P. Tommaso, Caitlin Hainy, Haitao Chu, M. Hassan Murad, Elie F. Berbari, Abinash Virk
Abstract
In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.
Topics & Concepts
MedicineCoronavirusCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CohortVirologySevere acute respiratory syndrome coronavirusMessenger RNADiseaseImmunologyInfectious disease (medical specialty)Internal medicineBiologyGeneBiochemistrySARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyViral gastroenteritis research and epidemiology